Current Diabetes Reports

, 18:113 | Cite as

Metabolic Surgery as a Treatment Option for Type 2 Diabetes Mellitus: Surgical View

  • Eric Rachlin
  • Carlos GalvaniEmail author
Therapies and New Technologies in the Treatment of Diabetes (M Pietropaolo, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Therapies and New Technologies in the Treatment of Diabetes


Purpose of Review

Type 2 diabetes mellitus (T2DM) is increasing in prevalence and associated with numerous metabolic complications leading to increased mortality and costs. Metabolic surgery, or surgery to treat T2DM and obesity, is effective at achieving remission from T2DM. This review discusses the most commonly used surgical options including the adjustable gastric band, the Roux-en-Y gastric bypass, the sleeve gastrectomy, and the biliopancreatic diversion with duodenal switch and their ability to treat and prevent T2DM.

Recent Findings

There is an increasing body of literature that justifies the inclusion of metabolic surgery into the treatment algorithm for patients with obesity and T2DM. Metabolic procedures should be performed at centers that offer comprehensive treatment of metabolic disorders and have expertise in gastrointestinal surgery. The incremental improvement in the quality and safety of metabolic surgery has significantly reduced the risk of serious post-operative complications.


Metabolic surgery is a safe and effective treatment option for obese patients with T2DM.


Type 2 diabetes Gastric sleeve Adjustable gastric band Biliopancreatic diversion with duodenal switch Gastric bypass Metabolic surgery 


Compliance with Ethical Standards

Conflict of Interest

Eric Rachlin and Carlos Galvani declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917–28. Scholar
  2. 2.
    Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in Diabetes among adults in the United States, 1988-2012. JAMA. 2015;314(10):1021–9. Scholar
  3. 3.
    Haslam DW, James WP. Obesity. Lancet. 2005;366(9492):1197–209.CrossRefGoogle Scholar
  4. 4.
    Olshansky SJ, Passaro DJ, Hershow RC, Layden J, Carnes BA, Brody J, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med. 2005;352(11):1138–45.CrossRefGoogle Scholar
  5. 5.
    Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289(1):76–9.CrossRefGoogle Scholar
  6. 6.
    Hage MP, Safadi B, Salti I, Nasrallah M. Role of gut-related peptides and other Hormones in the amelioration of type 2 diabetes after Roux-En-Y gastric bypass surgery. ISRN Endocrinol. 2012;2012:504756. Scholar
  7. 7.
    Rubino F, Schauer PR, Kaplan LM, Cummings DE. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med. 2010;61:393–411. Scholar
  8. 8.
    Guo Y, Huang ZP, Liu CQ, Qi L, Sheng Y, Zou DJ. Modulation of the gut microbiome: a systematic review of the effect of bariatric surgery. Eur J Endocrinol. 2018;178(1):43–56. Scholar
  9. 9.
    Peat CM, Kleiman SC, Bulik CM, Carroll IM. The intestinal microbiome in bariatric surgery patients. Eur Eat Disord Rev. 2015;23(6):496–503. Scholar
  10. 10.
    Daigle CR, Brethauer SA, Tu C, Petrick AT, Morton JM, Schauer PR, et al. Which postoperative complications matter most after bariatric surgery? Prioritizing quality improvement efforts to improve national outcomes. Surg Obes Relat Dis. 2018;14(5):652–7. Scholar
  11. 11.
    Gastrointestinal surgery for severe obesity. NIH consensus development conference, March 25-7, 1991. Nutrition 1996;12(6):397–404Google Scholar
  12. 12.
    Rubino F, Nathan DM, Eckel RH, Schauer PR, Alberti KG, Zimmet PZ, et al. Delegates of the 2nd Diabetes Surgery Summit metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care. 2016;39(6):861–77. Scholar
  13. 13.
    Mechanick JI, Youdim A, Jones DB, Garvey WT, Hurley DL, MM MM, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. Obesity (Silver Spring). 2013;21(Suppl 1):S1–27. Scholar
  14. 14.
    Edholm D, Kullberg J, Karlsson FA, Haenni A, Ahlström H, Sundbom M. Changes in liver volume and body composition during 4 weeks of low calorie diet before laparoscopic gastric bypass. Surg Obes Relat Dis. 2015;11(3):602–6. Scholar
  15. 15.
    Aberle J, Freier A, Busch P, Mommsen N, Beil FU, Dannheim V, et al. Treatment with sibutramine prior to Roux-en-Y gastric bypass leads to an improvement of metabolic parameters and to a reduction of liver size and operative time. Obes Surg. 2009;19(11):1504–7. Scholar
  16. 16.
    Parrott J, Frank L, Rabena R, Craggs-Dino L, Isom KA, Greiman L. American Society for Metabolic and Bariatric Surgery Integrated Health Nutritional Guidelines for the Surgical Weight Loss Patient 2016 Update: Micronutrients. Surg Obes Relat Dis. 2017;13(5):727–41. Scholar
  17. 17.
    O'Brien PE, MacDonald L, Anderson M, Brennan L, Brown WA. Long-term outcomes after bariatric surgery: fifteen-year follow-up of adjustable gastric banding and a systematic review of the bariatric surgical literature. Ann Surg. 2013;257(1):87–94. Scholar
  18. 18.
    Fielding GA, Allen JW. A step-by-step guide to placement of the LAP-BAND adjustable gastric banding system. Am J Surg. 2002;184(6B):26S–30S.CrossRefGoogle Scholar
  19. 19.
    Chang SH, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg. 2014;149(3):275–87. Scholar
  20. 20.
    Courcoulas AP, Belle SH, Neiberg RH, Pierson SK, Eagleton JK, Kalarchian MA, et al. Three-Year Outcomes of Bariatric Surgery vs Lifestyle Intervention for Type 2 Diabetes Mellitus Treatment: A Randomized Clinical Trial. JAMA Surg. 2015;150(10):931–40. Scholar
  21. 21.
    Altieri MS, Yang J, Telem DA, Meng Z, Frenkel C, Halbert C, et al. Lap band outcomes from 19,221 patients across centers and over a decade within the state of New York. Surg Endosc. 2016;30(5):1725–32. Scholar
  22. 22.
    Victorzon M, Tolonen P. Mean fourteen-year, 100% follow-up of laparoscopic adjustable gastric banding for morbid obesity. Surg Obes Relat Dis. 2013;9(5):753–7. Scholar
  23. 23.
    Benotti P, Wood GC, Winegar DA, Petrick AT, Still CD, Argyropoulos G, et al. Risk factors associated with mortality after Roux-en-Y gastric bypass surgery. Ann Surg. 2014;259(1):123–30. Scholar
  24. 24.
    El-Kadre L, Tinoco AC, Tinoco RC, Aguiar L, Santos T. Overcoming the learning curve of laparoscopic Roux-en-Y gastric bypass: a 12-year experience. Surg Obes Relat Dis. 2013;9(6):867–72. Scholar
  25. 25.
    Rodríguez A, Mosti M, Sierra M, Pérez-Johnson R, Flores S, Dominguez G, et al. Small bowel obstruction after antecolic and antegastric laparoscopic Roux-en-Y gastric bypass: could the incidence be reduced? Obes Surg. 2010;20(10):1380–4. Scholar
  26. 26.
    Yan Y, Sha Y, Yao G, Wang S, Kong F, Liu H, et al. Roux-en-Y Gastric bypass versus medical treatment for type 2 diabetes mellitus in obese patients: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016;95(17):e3462. Scholar
  27. 27.
    •• Adams TD, Davidson LE, Litwin SE, Kim J, Kolotkin RL, Nanjee MN, et al. Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med. 2017;377(12):1143–55. This study demonstrates one of the longest follow-up periods, 12 years, for patients undergoing metabolic surgery. It demonstrates the long-term efficacy of metabolic surgery in achieving weight loss and decrease in obesity-associated comorbidities. CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    • Maciejewski ML, Arterburn DE, Van Scoyoc L, Smith VA, Yancy WS Jr, Weidenbacher HJ, et al. Bariatric Surgery and Long-term Durability of Weight Loss. JAMA Surg. 2016;151(11):1046–55. This prospective cohort study shows the durability of weight loss with metabolic surgery over time. CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    •• Kabir A, Mousavi S, Pazouki A. The Complications of Bariatric Surgery Patients with Type 2 Diabetes in the World: A systematic Review and Meta-Analysis. Curr Diabetes Rev. 2018 . This review looks at complication rates of various metabolic procedures.
  30. 30.
    Wendling MR, Linn JG, Keplinger KM, Mikami DJ, Perry KA, Melvin WS, et al. Omental patch repair effectively treats perforated marginal ulcer following Roux-en-Y gastric bypass. Surg Endosc. 2013;27(2):384–9.CrossRefGoogle Scholar
  31. 31.
    Moon RC, Teixeira AF, Goldbach M, Jawad MA. Management and treatment outcomes of marginal ulcers after Roux-en-Y gastric bypass at a single high volume bariatric center. Surg Obes Relat Dis. 2014;10(2):229–34. Scholar
  32. 32.
    Estimate of bariatric surgery numbers, 2011–2017. American Society for Metabolic and Bariatric Surgery, Scholar
  33. 33.
    Mans E, Serra-Prat M, Palomera E, Suñol X, Clavé P. Sleeve gastrectomy effects on hunger, satiation, and gastrointestinal hormone and motility responses after a liquid meal test. Am J Clin Nutr. 2015;102(3):540–7. Scholar
  34. 34.
    Yousseif A, Emmanuel J, Karra E, Millet Q, Elkalaawy M, Jenkinson AD, et al. Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans. Obes Surg. 2014;24(2):241–52. Scholar
  35. 35.
    Stenard F, Iannelli A. Laparoscopic sleeve gastrectomy and gastroesophageal reflux. World J Gastroenterol. 2015;21(36):10348–57. Scholar
  36. 36.
    Kim M, Navarro F, Eruchalu CN, Augenstein VA, Heniford BT, Stefanidis D. Minimally invasive Roux-en-Y gastric bypass for fundoplication failure offers excellent gastroesophageal reflux control. Am Surg. 2014;80(7):696–703.PubMedGoogle Scholar
  37. 37.
    Madalosso CA, Gurski RR, Callegari-Jacques SM, Navarini D, Thiesen V, Fornari F. The impact of gastric bypass on gastroesophageal reflux disease in patients with morbid obesity: a prospective study based on the Montreal Consensus. Ann Surg. 2010;251(2):244–8. Scholar
  38. 38.
    •• Peterli R, Wölnerhanssen BK, Vetter D, Nett P, Gass M, Borbély Y, et al. Laparoscopic sleeve gastrectomy versus Roux-Y-gastric bypass for morbid obesity-3-year outcomes of the prospective randomized Swiss Multicenter Bypass Or Sleeve Study (SM-BOSS). Ann Surg. 2017;265(3):466–73. A randomized controlled trial comparing RYGB and SG over a 3 year period. CrossRefPubMedGoogle Scholar
  39. 39.
    •• Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, et al. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med. 2017;376(7):641–51. A randomized controlled trial comparing medical management to RYGB to SG over a 5 year period. CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Arterburn DE, Olsen MK, Smith VA, Livingston EH, Van Scoyoc L, Yancy WS Jr, et al. Association between bariatric surgery and long-term survival. JAMA. 2015;313(1):62–70. Scholar
  41. 41.
    Sjöström L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden Å, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311(22):2297–304. Scholar
  42. 42.
    Brethauer SA, Aminian A, Romero-Talamás H, Batayyah E, Mackey J, Kennedy L, et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg. 2013;258(4):628–36; discussion 636-7. Scholar
  43. 43.
    Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366(17):1567–76. Scholar
  44. 44.
    Shoar S, Saber AA. Long-term and midterm outcomes of laparoscopic sleeve gastrectomy versus Roux-en-Y gastric bypass: a systematic review and meta-analysis of comparative studies. Surg Obes Relat Dis. 2017;13(2):170–80. Scholar
  45. 45.
    •• Salminen P, Helmiö M, Ovaska J, Juuti A, Leivonen M, Peromaa-Haavisto P, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss at 5 years among patients with morbid obesity: the SLEEVEPASS Randomized Clinical Trial. JAMA. 2018;319(3):241–54. A randomized controlled trial comparing SG and RYGB over a 5-year period. CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    •• Melissas J, Stavroulakis K, Tzikoulis V, Peristeri A, Papadakis JA, Pazouki A, et al. Sleeve gastrectomy vs Roux-en-Y gastric bypass. Data from IFSO-European Chapter Center of Excellence Program. Obes Surg. 2017;27(4):847–55. A large cohort study comparing SG and RYGB. CrossRefPubMedGoogle Scholar
  47. 47.
    • Risstad H, Søvik TT, Engström M, Aasheim ET, Fagerland MW, Olsén MF, et al. Five-year outcomes after laparoscopic gastric bypass and laparoscopic duodenal switch in patients with body mass index of 50 to 60: a randomized clinical trial. JAMA Surg. 2015;150(4):352–61. Scholar
  48. 48.
    Biertho L, Lebel S, Marceau S, Hould FS, Julien F, Biron S. Biliopancreatic diversion with duodenal switch: surgical technique and perioperative care. Surg Clin North Am. 2016;96(4):815–26. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Michael E. DeBakey Department of SurgeryBaylor College of MedicineHoustonUSA

Personalised recommendations